Glenmark launches generic cancer treatment drug in US
Glenmark Pharmaceuticals on Tuesday said it has launched a cancer treatment generic medication in the US market. Glenmark Pharmaceuticals Inc., USA, a subsidiary of the Mumbai-based drug firm, will launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, it said in a statement. Glenmark’s product is therapeutically equivalent to the reference listed drug…